Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases
Real-world outcomes in this older and frailer patient cohort align with phase 3 trial results, further supporting selpercatinib as the standard of care for patients with <i>RET</i>-altered cancers. Early testing for the detection of <i>RET</i> alterations remains essential.
Authors
- Carmen Gonzalez-Ferrer
- Naleen Raj Bhandari (ORCID: https://orcid.org/0000-0002-4452-8021)
- Scott Barker (ORCID: https://orcid.org/0000-0001-9372-6932)
- Samuel Whipple (ORCID: https://orcid.org/0000-0001-7943-938X)
- Chi-Yin Liao (ORCID: https://orcid.org/0000-0001-8593-9970)
- Patrick Peterson (ORCID: https://orcid.org/0009-0004-9692-8897)
- Feng Wang (ORCID: https://orcid.org/0000-0003-1089-3095)
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-15
- DOI
- https://doi.org/10.3390/cancers16223835
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Eli Lilly and Company